## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($312.85)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Investors to Connect**
- Source: ABC4 Utah | 20251204T220838 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (NYSE:ELV) concerning potential corporate wrongdoing. The firm is encouraging investors who purchased Elevance securities prior to April 18, 2024, and continue to hold them, to connect with the firm to assist in the investigation. There is no cost to investors for participation, as the firm operates on a contingency fee basis.

**2. Elevance Health, Inc. (NYSE:ELV) to Issue Quarterly Dividend of $1.71**
- Source: MarketBeat | 20251204T170740 | Somewhat-Bullish | Relevance: 100%
- Elevance Health, Inc. (NYSE:ELV) has declared a quarterly dividend of $1.71 per share, payable on December 19th to shareholders of record on December 5th. The company has a strong dividend history, having raised its dividend for 14 consecutive years, and analysts anticipate it will continue to cover its dividend with an expected future payout ratio of 17.5%. Elevance Health recently beat Q3 earnings expectations with EPS of $6.03 and revenues of $50.09 billion, leading to a "Moderate Buy" consensus rating from analysts with an average target price of $398.44.

**3. Invesco Ltd. Has $821.94 Million Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251204T120812 | Bullish | Relevance: 100%
- Invesco Ltd. slightly reduced its stake in Elevance Health, Inc. by 0.1% in the second quarter, maintaining a substantial position valued at approximately $821.94 million. Institutional investors collectively own 89.24% of Elevance Health, with several other hedge funds also adjusting their holdings. Analysts generally show positive sentiment towards ELV, giving it a "Moderate Buy" rating with a consensus price target of $398.44.

**4. Panagora Asset Management Inc. Cuts Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251204T000812 | Neutral | Relevance: 100%
- Panagora Asset Management Inc. reduced its stake in Elevance Health (NYSE:ELV) by 8.9% in Q2, selling 4,240 shares and retaining 43,219 shares valued at $16.81 million. Despite this reduction, Elevance Health exceeded Q3 earnings and revenue estimates, reporting EPS of $6.03 and $50.09 billion in revenue, up 12% year-over-year. Analysts currently hold a consensus "Hold" rating with a target price of $398.44, and the company has declared a quarterly dividend of $1.71.

**5. Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets**
- Source: ts2.tech | 20251203T010202 | Neutral | Relevance: 100%
- This article provides an in-depth outlook on Elevance Health (ELV) stock as of December 2025, following its Q3 earnings beat. It details the company's financial performance, stock valuation, and ongoing legal and regulatory challenges, including Medicare Advantage star ratings disputes and securities lawsuits. The report also highlights new analyst targets, institutional buying, and key risks and opportunities for investors considering ELV for 2026 and beyond.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.3 |
| Current P/E | 11.0 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.0% to -0.4% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.06), confirming momentum. RSI neutral at 51. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.43% (CS: 50) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | 1.06 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $330.75
- **Stop Loss:** $312.85 (5.4% risk)
- **Target:** $366.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $8,930.25
- **Portfolio %:** 8.93%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*